key: cord-0791414-mzdedixh
authors: Rodrigues, T. S.; Sa, K. S.; Ishimoto, A. Y.; Becerra, A.; Oliveira, S.; Almeida, L.; Goncalves, A. V.; Perucello, D. B.; Andrade, W. A.; Castro, R.; Veras, F. P.; Toller-Kawahisa, J. E.; Nascimento, D. C.; de Lima, M. H.; Silva, C. M.; Caetite, D. B.; Martins, R. B.; Castro, I. A.; Pontelli, M. C.; de Barros, F. C.; do Amaral, N. B.; Giannini, M. C.; Bonjorno, L. P.; Lopes, M. I. F.; Benatti, M. N.; Santana, R. C.; Vilar, F. C.; Auxiliadora-Martins, M.; Luppino-Assad, R.; de Almeida, S. C.; de Oliveira, F. R.; Batah, S. S.; Siyuan, L.; Cunha, T. M.; Alves-Filho, J. C.; Cunha,
title: Inflammasome activation in COVID-19 patients
date: 2020-08-06
journal: nan
DOI: 10.1101/2020.08.05.20168872
sha: eadc14ea7ad44ef6accf161a2fbb9e691ffcc6c6
doc_id: 791414
cord_uid: mzdedixh

Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1{beta} and IL-18. Although the participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease is unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and it is active in COVID-19, influencing the clinical outcome of the disease. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of post-mortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that the inflammasome is key in the pathophysiology of the disease, indicating this platform as a marker of disease severity and a potential therapeutic target for COVID-19.

statistically significant differences for IL-2, TNF-a, and IL-17A ( Fig. 2C and Fig.  117   S1 ). IFN-g levels were slightly lower in COVID-19 patients as compared to controls 118 ( Fig. S1) . Next, we measured inflammasome activation in peripheral blood 119 mononuclear monocytes (PBMCs) from 47 patients and compared them with 32 120 healthy individuals. Using the FAM-YVAD assay that stains active intracellular 121 caspase-1 11 , we found that, on the day of hospitalization, the PBMCs from patients 122

show a higher percentage of FAM-YVAD+ cells as compared to healthy controls 123 ( Fig. 2D-E) . Microscopy observation of these cells allows clear visualization of 124 NLRP3 puncta in PBMCs, indicating active inflammasomes in patients cells (Fig. 2F -125 G). We further confirmed caspase-1 activation using a luminescent assay and found 126 active caspase-1 in supernatants from 46 patients PBMCs cultures, as opposed to low 127 caspase-1 activation in healthy donors (Fig. 2H) . We also detected IL-1b in the 128 supernatants of PBMCs from some patients, but not from healthy donors (Fig. 2I) , 129 further supporting inflammasome activation in PBMCs from COVID-19 patients. 130 131 We further assessed inflammasome activation in lung tissues obtained from 132 autopsies of deceased COVID-19 patients. Using an anti-SARS-CoV-2 antibody, we 133 first confirmed viral presence by immunohistochemical staining SARS-CoV-2 in 134 injured regions of post-mortem lung tissues (Fig. 3A,B) . We then performed 135

Multiplex Staining by Sequential Immunohistochemistry with SARS-CoV-2, anti-136 CD14, and anti-NLRP3 and identified infected CD14+ cells expressing NLRP3 in 137 post-mortem tissues (Fig. 3C, D) . Using multiphoton microscopy, we quantified the 138 number of NLRP3 puncta in tissues 5 controls and 6 COVID-19 patients and found 139 that patients contain higher numbers of NLRP3 puncta as compared to controls. (Fig.  140   3E) . Images of tissues stained with anti-NLRP3 antibody illustrates NLRP3 puncta in 141 of lethal cases of COVID-19 ( Fig. 3F-I) . We observed NLRP3 puncta inside cells in 142 the tissues and also cells contained in venules (Fig. 3I) , unequivocally demonstrating 143 activation of the NLRP3 inflammasome in fatal cases of COVID-19. 144 145 We next assessed the impact of the inflammasome activation in the clinical 146 outcome of the disease. Initially, we performed analyses using the levels of Casp1p20 147 and IL-18 in 124 patients sera obtained on the day of hospitalization. A correlation 148 matrix show association of Casp1p20 and IL-18 levels with patient characteristics and 149 clinical parameters (Fig. 4A) . As expected, we found a positive correlation between 150 Casp1p20 and IL-18 levels (Fig. 4B ). In addition, Casp1p20 positively correlated 151 with IL-6, LDH and C-reactive protein (CRP) (Fig. 4C-E) . Furthermore, we found 152 that IL-18 levels positively correlated with IL-6 and CRP levels (Fig. 4F, G) . We also 153 evaluated if the levels of Casp1p20 and IL-18 were affected by patients comorbidities 154 and clinical parameters, including bacterial co-infections (cultivable bacteria in the 155 blood), nephropathy, obesity, gender, cerebrovascular accident, pneumopathy, 156 immunodeficiency and neoplasia (Fig. S2) . We only detected statistically significant 157 differences when we compared obese with non-obese patients, as the levels of IL-18 158 were higher in patients with body mass index ³ 30 (Fig. S2G) . 159 160 Next, we investigated if Casp1p20 and IL-18 levels measured on the day of 161 hospitalization correlated with the clinical outcome of the disease. Importantly, we 162 found that IL-18, but not Casp1p20 were higher in patients who required mechanical 163 ventilation (MV) as compared with patients that did not (Fig. 4H, I) . When we 164 separated the patients according to the severity of the disease (mild/moderate versus 165 severe), we found that the levels of Casp1p20 but not IL-18 were higher in patients 166 with the severe form of COVID-19 (Fig. 4J, K) . We also observed that the levels of 167 IL-18, but not Casp1p20, were higher in lethal cases of COVID-19 as compared to 168 survivors (Fig. 4L, M) . Finally, we performed longitudinal analyses of IL-18 and 169 Casp1p20 production in 37 patients from the day of hospitalization (day zero) for up 170 to 45 days post-admission using generalized mixed models with 'gamma' distribution 171 and 'log' link function as the best dataset prediction. For these analyses, we 172 categorized the patients as Death, Mild-Recovery (patients that were hospitalized but 173 did not require mechanical ventilation and recovered), and Critical-Recovery (patients 174 that required mechanical ventilation at the Intensive Care Unit (ICU) and recovered) 175 (Supplemental data). For Casp1p20, the most parsimonious model indicated a 176 significant effect of the day sampled, and the production level decreased with time 177 regardless of sex or patient outcome (Fig. 4N , and Supplemental data). For IL-18, 178 the best-fit model retained also described an overall reduction in IL-18 production 179 along time (Day sampled), which differed among patient groups. This model 180 predicted a decrease in IL-18 at similar rates among the three groups, with patients 181 that died presenting higher levels (intercept) that never reached those observed in 182 mild and critical recovered patients ( Fig. 4O and Supplemental data), supporting our 183 assertion that the magnitude of inflammasome activation impacts the disease 184 outcome. In summary, our data demonstrate that the inflammasome is robustly active 185 in COVID-19 patients requiring hospitalization. It also supports that both the 186 magnitude of inflammasome activation at the hospitalization day and the course of 187 inflammasome activation during hospitalization influenced the clinical outcome. Patients were enrolled in HC-FMRP/USP from April 06 to July 02, 2020 and instructions. The material was centrifuged at 400 x g for 10 minutes at room 217 temperature. Then, the plasma was discarded and the cell pellet was resuspended in 218 PBS 1X pH 7.4 (GIBCO, BRL). The cells were applied to the Ficoll-PaqueTM PLUS 219 gradient column (GE Healthcare Biosciences AB, Uppsala, Sweden). Then, they were 220 centrifuged at 640 x g for 30 minutes at room temperature to obtain the purified 221 mononuclear fraction, which was carefully collected and transferred to a new tube. 222

The cells were washed and the pellet was resuspended in RPMI for the subsequent 223 To measure caspase-1 activity, the supernatants were collected, and incubated with 299 the Luciferin WEHD-substrate provided by the Caspase-Glo 1 Assay (Promega). 300

After 1 hour incubation at room temperature, luminescence was measured using 301 

Inflammasomes: mechanism of assembly, regulation 447 and signalling

The hierarchical structural architecture 450 of inflammasomes, supramolecular inflammatory machines. Current opinion 451 in structural biology 31

Neutrophil elastase promotes interleukin-1beta secretion 453 from human coronary endothelium

Caspase 1-independent activation of interleukin-1beta in 456 neutrophil-predominant inflammation

Inflammatory arthritis in caspase 1 gene-deficient mice: 459 contribution of proteinase 3 to caspase 1-independent production of bioactive 460 interleukin-1beta

The Birc1e cytosolic pattern-recognition receptor 463 contributes to the detection and control of Legionella pneumophila infection

Detection of 2019 novel coronavirus (2019-nCoV) by 466 real-time RT-PCR. Euro surveillance : bulletin Europeen sur les maladies 467 transmissibles =

Comparative Performance of SARS-CoV-2 Detection 470

Assays Using Seven Different Primer-Probe Sets and One Assay Kit

Characteristics of and Important Lessons From 473 the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a 474 Report of 72314 Cases From the Chinese Center for Disease Control and 475 Prevention

Laparoscopic vs 477 conventional autopsy. A promising perspective

Laparoscopic postmortem examination: a minimally invasive approach 481 to the autopsy

The Th17 pathway in the peripheral lung microenvironment 486 interacts with expression of collagen V in the late state of experimental 487 pulmonary fibrosis

American 490 journal of respiratory and critical care medicine 200

glmmTMB Balances Speed and Flexibility Among 493 Packages for Zero-inflated Generalized Linear Mixed Modeling

Multi-Model Inference. R package version 1.43

Model Selection and Multimodel 498 Inference: a practical information-theoretic approach

Residual Diagnostics for Hierarchical

Mixed) Regression Models

ggeffects: Tidy Data Frames of Marginal Effects from Regression 503

mixed: Tidying Methods for Mixed Models